Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

iCARE4CVD Individualised Care from Early Risk of Cardiovascular Disease to Established Heart Failure

Coordinator
Universiteit Maastricht, Netherlands
Runs
1 October 2023 to 31 March 2028
Status
Running
EU funding
€9.9m
Total cost
€21.5m
Partners
47 organisations in 15 countries
Type
Research and Innovation Action
Grant agreement
101112022

What the project is doing

In the project's own words, from its summary on CORDIS.

The burden of cardiovascular disease (CVD) on society is huge with >85 million people affected in Europe. The overall prevalence continues to grow due to unhealthy lifestyles and population aging. Heart failure (HF) is the final common pathway of all CVD and has a 5 year mortality rate of 20-50% despite significant advances in therapy.iCARE4CVD aims to address this burden by contributing to three essential steps to improve the current care pathways, covering all stages from early risk to established HF: 1) early diagnosis to identify patients at risk of CVD and divide them into clinically meaningful subgroups; 2) risk stratification for these subgroups to define the urgency for intervention; and 3) prediction of treatment response for each subgroup.

This will be achieved by the following steps: clinical partners will provide a large set of cohorts including >1,000,000 patients with a wide range of biomarkers (e.g. digital, blood, imaging). Anonymous access to data will be enabled by using a blockchain-supported federated database. Artificial intelligence-based modeling also considering patient relevant factors will assess changes in risk and stratify patients according to their individual responses to therapy.

Results will then be prospectively validated in new and ongoing large cohorts and a pilot trial to test the prediction of treatment response by using multiple biomarkers going beyond current risk prediction (such as SCORE) towards individualized therapy. Results will be used to provide novel decision tools for each step targeting newly identified subgroups and as a blueprint for innovative future trials to individualise prevention and therapy.

Patient involvement is key in every part of iCARE4CVD (e.g. patient advisory board, country-specific Patient Panels) to build a motivational framework for self-care by patients. The project brings together an EU-wide consortium with the needed resources and expertise from the public and private side to bring iCARE4CVD to success.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit MaastrichtMaastrichtNetherlandsCoordinator
Medizinische Universitaet WienWienAustriaParticipant
AmgenDiegemBelgiumParticipant
Huawei Technologies Research & Development BelgiumGentBelgiumAssociatedpartner
Thomas More Kempen VzwGeelBelgiumParticipant
Decentriq AGZurichSwitzerlandParticipant
Eli Lilly Export SAVernierSwitzerlandAssociatedpartner
Exploris Health AGWallisellenSwitzerlandAssociatedpartner
F. Hoffmann-La Roche AGBaselSwitzerlandParticipant
Sib Swiss Institute of BioinformaticsGenfSwitzerlandAssociatedpartner
Bayer AktiengesellschaftLeverkusenGermanyParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Deutsche Stiftung Fur Chronisch KrankeFurthGermanyParticipant
Evotec International GmbHHamburgGermanyParticipant
Lilly Deutschland GmbHBad HomburgGermanyAssociatedpartner
Universitaetsklinikum AachenAachenGermanyParticipant
Wig2 GmbHLeipzigGermanyParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Bayer Hispania SLSant Joan DespiSpainThird party
Huawei Technologies Oy (finland) Co LtdHelsinkiFinlandParticipant
Precordior OyTurkuFinlandParticipant
Bayer Healthcare SASLoosFranceThird party
Fondation Francophone Pour La Recherche Sur Le DiabeteParisFranceParticipant
Huawei Technologies FranceBoulogne-BillancourtFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Capsicohealthcare LimitedDublinIrelandParticipant
University College Dublin, National University of Ireland, DublinDublinIrelandParticipant
Fondazione Human TechnopoleMilanoItalyParticipant
Istituto Di Ricerche Farmacologiche Mario NegriMilanoItalyParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Academisch Ziekenhuis MaastrichtMaastrichtNetherlandsParticipant
Ancora Health BVGroningenNetherlandsParticipant
Catalyze B.V.Amsterdam-DuivendrechtNetherlandsParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek TNODen HaagNetherlandsParticipant
Philips Medical Systems Nederland BVBestNetherlandsParticipant
Stichting IMEC NederlandEindhovenNetherlandsParticipant
Astrazeneca ABSodertaeljeSwedenParticipant
Orbital Global Group LimitedStowmarketUnited KingdomAssociatedpartner
The Queen's University of BelfastBelfastUnited KingdomAssociatedpartner
University of GlasgowGlasgowUnited KingdomAssociatedpartner
University of UlsterColeraineUnited KingdomAssociatedpartner
Bayer Healthcare LlcWhippanyUnited StatesThird party
Breakthrough T1dNew YorkUnited StatesParticipant
Eli Lilly and CompanyIndianapolisUnited StatesParticipant
University of Cape TownRondeboschSouth AfricaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI